Recce Pharmaceuticals Ltd
RCE
Rank in Stocks
#21122
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating... Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Share Price
$0.23880556
Last synced: 2026-11-10
Market Cap
$73.04M
Change (1 day)
0.00%
Change (1 year)
-15.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Recce Pharmaceuticals Ltd (RCE)
Category
Healthcare
Operating Margin for Recce Pharmaceuticals Ltd (RCE)
Operating Margin as of November 2026 TTM: 0.00%
According to Recce Pharmaceuticals Ltd's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -304.71%.
Operating Margin history for Recce Pharmaceuticals Ltd from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -304.71% | -30.52% |
| 2024 | -438.54% | 10.49% |
| 2023 | -396.90% | -13.47% |
| 2022 | -458.69% | -51.12% |
| 2021 | -938.36% | 94.64% |
| 2020 | -482.10% | -4.17% |
| 2019 | -503.09% | 121.96% |
| 2018 | -226.66% | -90.09% |
| 2017 | -2,286.23% | -16.06% |
| 2016 | -2,723.60% | 589.22% |
| 2015 | -395.17% | 41.03% |
| 2014 | -280.20% | -99.63% |
| 2013 | -75,536.43% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Recce Pharmaceuticals Ltd's operating margin
What was Recce Pharmaceuticals Ltd's operating margin in 2025?
In 2025, Recce Pharmaceuticals Ltd's operating margin was -304.71%, compared with -438.54% in 2024.
How has Recce Pharmaceuticals Ltd's operating margin changed since 2020?
From 2020 to 2025, Recce Pharmaceuticals Ltd's operating margin was highest in 2025 (-304.71%) and lowest in 2021 (-938.36%).
How does Recce Pharmaceuticals Ltd's operating margin compare with similar companies?
Recce Pharmaceuticals Ltd's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.